Program Schedule

Potential Public Health Impact of Having Included N. meningitidis Serogroup B in the 2005 Recommendation for Adolescent Meningococcal Serogroup A, C, Y, and W-135 Vaccination

Session: Poster Abstract Session: Public Health
Saturday, October 11, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
  • MNB14185.3011.pdf (956.4 kB)
  • Background:

    Routine conjugate vaccination against IMD caused by N meningitidis serogroups A, C, W-135 and Y (MenACWY)  began in the United States in 2005, with a single dose of MnACWY vaccine given at age 11 years, and later augmented to include a booster dose at age 16 years.  At that time, there was no licensed, broadly protective vaccine against serogroup B (MenB), which represented half of the IMD cases reported in children aged 5-17 in the US. We estimated the potential historical public health impact, measured in cases of invasive meningococcal disease (IMD) avoided, if an adolescent MenB vaccine had been available and included in the 2005 recommendation.


    A transmission dynamic model was developed to simulate prevalence of meningococcal carriage and incidence of IMD within the US population over the past 10 years following initiation of the five serogroup adolescent vaccination program. Carriage prevalence and vaccine efficacy against IMD and carriage were obtained from the published literature and expert opinion. Sensitivity analyses were performed with recent IMD incidence estimates from the national surveillance system in 2005 and 2012. Cases and deaths averted were calculated.


    The model estimated that 784 serogroup B IMD cases and 73 deaths would have been prevented through 2014, if a MnB vaccine had been similarly implemented in 2005 (Figure, top line). At 2012 epidemiology, the cases and deaths avoided would have been 77 and 7, respectively (Figure, bottom line).


    IMD incidence, including that of serogroup B, has declined in the US over the past 15 years.  IMD is severe and unpredictable, and it is unknown whether incidence will remain low. While the impact of a MnB vaccine at current epidemiology will be limited, had a MenB vaccine been available and recommended alongside MenACWY in the US, substantial disease avoidance could have been realized over the past 10 years.


    Sonya J. Snedecor, PhD1, Raymond Farkouh, PhD2, Laura York, PhD2, Mei Xue, MBA1 and David Strutton, PhD3, (1)Pharmerit International, Bethesda, MD, (2)Pfizer Inc, Collegeville, PA, (3)Pfizer Inc., Collegeville, PA


    S. J. Snedecor, Pharmerit: Employee, Consulting fee

    R. Farkouh, Pfizer: Employee, Salary

    L. York, Pfizer: Employee, Salary

    M. Xue, Pharmerit: Employee, Consulting fee

    D. Strutton, Pfizer: Employee, Salary

    See more of: Public Health
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, All Rights Reserved.

    Follow IDWeek